Pulmonary microthrombi during left ventricular assist device implantation

Texas Heart Institute Journal

Volumn 32, Issue 2, 2005, Pages 228-231

  Gregoric, Igor D ^a   Patel, Vijay ^a   Radovancevic, Rajko ^a   Bracey, Arthur W ^a   Radovancevic, Branislav ^a   Frazier, O H ^a,b  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b TEXAS HEART INSTITUTE   (United States)

Author keywords

Aprotinin administration dosage adverse effects; Blood coagulation drug effects; Blood loss, surgical prevention and control; Heart failure, congestive; Heart assist devices adverse effects; Heparin; Postoperative complications mortality

Indexed keywords

AMIODARONE; APROTININ; BUMETANIDE; CEFEPIME; DOBUTAMINE; DOPAMINE; PROTAMINE; TISSUE PLASMINOGEN ACTIVATOR; VANCOMYCIN; VASOPRESSIN;

ADULT; ARTICLE; BLEEDING; CARDIOPULMONARY BYPASS; CASE REPORT; DISEASE COURSE; FEMALE; HEART ASSIST DEVICE; HEART LEFT VENTRICLE; HEART TRANSPLANTATION; HEPARINIZATION; HISTOPATHOLOGY; HUMAN; IMPLANTATION; LUNG ARTERY PRESSURE; LUNG ARTERY THROMBOSIS; MICROTHROMBUS; THROMBOEMBOLISM; THROMBOSIS;

BLOOD COAGULATION; BLOOD PRESSURE; FEMALE; HEART-ASSIST DEVICES; HUMANS; INTRAOPERATIVE COMPLICATIONS; MIDDLE AGED; PLASMINOGEN ACTIVATORS; PULMONARY ARTERY; PULMONARY EMBOLISM; TISSUE PLASMINOGEN ACTIVATOR;

EID: 20444380006     PISSN: 07302347     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Frazier OH, Rose EA, McCarthy P, Burton NA, Tector A, Levin H, et al. Improved mortality and rehabilitation of transplant candidates treated with a long-term implantable left ventricular assist system. Ann Surg 1995;222:327-38.
2. Goldstein DJ, Seldomridge JA, Chen JM, Catanese KA, DeRosa CM, Weinberg AD, et al. Use of aprotinin in LVAD recipients reduces blood loss, blood use, and perioperative mortality. Ann Thorac Surg 1995;59:1063-8.
3. Royston D, Bidstrup BP, Taylor KM, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2:1289-91.
4. Royston D. Aprotinin therapy in heart and heart-lung transplantation. J Heart Lung Transplant 1993;12(1 Pt 1):S19-25.
5. Bracey A, Radovancevic R, Radovancevic B, Chen RH, Vaughn W, McAllister H, Frazier OH, Cooley DA. Decreased bleeding and blood requirements during heart transplantation by hemostatic drugs. Transfusion 1995;35(10S); S251.
6. Sundt TM 3rd, Kouchoukos NT, Saffitz JE, Murphy SF, Wareing TH, Stahl DJ. Renal dysfunction and intravascular coagulation with aprotinin and hypothermic circulatory arrest. Ann Thorac Surg 1993;55:1418-24.
7. Westaby S. Aprotinin in perspective. Ann Thorac Surg 1993;55:1033-41.
8. Cosgrove DM 3rd, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LA, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54:1031-8.
9. Royston D. Intraoperative coronary thrombosis: can aprotinin be incriminated? J Cardiothorac Vasc Anesth 1994;8:137-41.
10. Dietrich W, Dilthey G, Spannagl M, Jochum M, Braun SL, Richter JA. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study. Anesthesiology 1995;83:679-89; 29A-30A.
11. Ogston D. The fibrinolytic enzyme system. In: Ogston D, editor. Antifibrinolytic drugs: chemistry, pharmacology, and clinical usage. New York: Wiley; 1984. p. 5-45.
12. Marsh NA. The fibrinolytic enzyme system. In: Francis JL, editor. Fibrinogen, fibrin stabilisation, and fibrinolysis: clinical, biochemical, and laboratory aspects. Chichester (England): Ellis Horwood; 1988. p. 223-63.
13. Valeri CR, Feingold H, Cassidy G, Ragno G, Khuri S, Altschule MD. Hypothermia-induced reversible platelet dysfunction. Ann Surg 1987;205:175-81.
14. Tanaka K, Takao M, Yada I, Yuasa H, Kusagawa M, Deguchi K. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiothorac Anesth 1989;3:181-8.
15. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101:958-67.
16. Havel M, Teufelsbauer H, Knobl P, Dalmatiner R, Jaksch P, Zwolfer W, et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg 1991;101:968-72.